ScionxBio is launched from Eleven Therapeutics, appoints Dr. Adi Gilboa-Geffen as CEO

BOSTON - EntSun -- ScionxBio, a preclinical-stage RNA therapeutics company, today announces its emergence from stealth, after completing a strategic horizontal split by Eleven Therapeutics. ScionxBio will advance a groundbreaking xRNA modality, a next-generation mRNA therapeutic, and its cardio-metabolic asset pipeline. Dr. Adi Gilboa-Geffen, Eleven's former CTO, has been appointed as ScionxBio's CEO. Dr. Yaniv Erlich, co-founder and former CEO of Eleven Therapeutics, joins ScionxBio as Co-Founder and Chairman of the Board of Directors. Shaul Ilan, co-founder of Eleven Therapeutics, joins ScionxBio as Co-Founder, COO, and Board Member.

ScionxBio is the continuation of Eleven Therapeutics' xRNA mission: an asset-focused company with a validated platform, a defined pipeline, and single focus - developing long-acting xRNA therapeutics for cardio-metabolic disease.

More on EntSun News

• July 4th patriotic Drone Light Show for community
• Sterling Style Academy Announces Standalone Online Color Analysis Training Utilizing Proprietary Three-Dimensional Evaluation Method
• PoLo Jose's Powerful Drama Dissection of the Dollar Now Streaming on Tubi
• 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
• MetroLagoons announces Christmas in July celebration July 24-26

ScionxBio's xRNA platform is built on the company's proprietary TERÅ® technology, which uses combinatorial chemistry and deep-learning architectures to engineer RNA molecules with significantly enhanced structural stability and resistance to enzymatic degradation. ScionxBio is applying xRNA to cardio-metabolic disease, where long-acting, consistent protein expression has direct implications for patient burden, treatment durability, and the immunogenic risk associated with repeat administration.

"I have spent my career building things that did not exist, always alongside great teams and great scientists. The years I spent at Eleven Therapeutics, leading the research together with Yaniv and the team, were no different. We asked whether we could engineer RNA to last. Today, we have a proven modality, validated data, and a pipeline ready to move. The science phase is behind us. What comes next is building medicines.

"Patients with chronic metabolic disease face a lifetime of frequent dosing - and with it, accumulated immunogenic risk, side effects, and exposure peaks and troughs. Long-acting xRNA addresses all of that. Sustained expression. Significantly reduced immunogenic burden. A different class of medicine."

More on EntSun News

• Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
• Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
• Elklook Independence Day: What You Need to Know
• Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
• OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities

- Dr. Adi Gilboa-Geffen, PhD, CEO and Board Member

ABOUT SCIONXBIO

ScionxBio, formerly Eleven Therapeutics, is a Cambridge-based preclinical biotechnology company developing long-acting, programmable xRNA therapeutics for cardio-metabolic disease. The company's TERÅ® platform applies combinatorial chemistry and deep learning to engineer RNA molecules with exceptional stability and sustained protein expression, enabling infrequent dosing and consistent therapeutic effect. ScionxBio emerged from stealth, having operated independently since January 2026 following the completion of a horizontal split by Eleven Therapeutics, with a focused mission to develop next-generation xRNA therapeutics for cardio-metabolic disease.

Dr. Adi Gilboa-Geffen, CEO - ScionxBio
press@scionxbio.com | http://www.scionxbio.com

This press release contains forward-looking statements. Actual results may differ materially. ScionxBio undertakes no obligation to update such statements.

Written to endure.